VCYT:NSD-Veracyte Inc. (USD)

EQUITY | Diagnostics & Research | NASDAQ Global Market

Last Closing

USD 34.32

Change

+0.69 (+2.05)%

Market Cap

USD 0.21B

Volume

0.93M

Analyst Target

USD 38.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Veracyte Inc is engaged in the discovery, development and commercialization of molecular cytology solutions that enable physicians to make more informed treatment decisions at an early stage in patient treatment.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-17 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

-0.97 (-0.19%)

USD 41.20B
ICLR ICON PLC

+9.91 (+3.39%)

USD 24.84B
ILMN Illumina Inc

+0.76 (+0.58%)

USD 20.58B
NTRA Natera Inc

-0.11 (-0.09%)

USD 15.65B
EXAS EXACT Sciences Corporation

+1.22 (+1.79%)

USD 11.40B
MEDP Medpace Holdings Inc

+6.64 (+1.87%)

USD 10.90B
RDNT RadNet Inc

+0.30 (+0.45%)

USD 5.01B
SHC Sotera Health Co

+0.08 (+0.48%)

USD 4.76B
NEOG Neogen Corporation

+0.37 (+2.19%)

USD 3.50B
GH Guardant Health Inc

-0.01 (-0.04%)

USD 3.30B

ETFs Containing VCYT

ARCG:LSE ARK Genomic Revolution UC.. 4.15 % 0.00 %

-10.00 (-2.35%)

USD 2.92M
ARKG:LSE ARK Genomic Revolution UC.. 4.13 % 0.00 %

-0.12 (-2.35%)

USD 2.92M
ARKG 4.13 % 0.75 %

N/A

N/A
GNOM Global X Genomics & Biote.. 4.01 % 0.00 %

-0.09 (-2.35%)

USD 0.08B
GN0M:XETRA Global X Genomics & Biote.. 4.00 % 0.00 %

-0.08 (-2.35%)

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 4.00 % 0.00 %

-0.04 (-2.35%)

USD 6.07M
GNOG:LSE Global X Genomics & Biote.. 3.99 % 0.00 %

-0.09 (-2.35%)

USD 5.90M
XMLH:XETRA L&G Healthcare Breakthrou.. 1.96 % 0.00 %

-0.13 (-2.35%)

USD 0.07B
XMLH:F Legal & General Ucits Etf.. 1.96 % 0.00 %

+0.06 (+-2.35%)

USD 0.07B
DOCT:SW L&G Healthcare Breakthrou.. 1.96 % 0.00 %

-0.05 (-2.35%)

USD 0.07B
DOCT:LSE L&G Healthcare Breakthrou.. 1.93 % 0.00 %

-0.15 (-2.35%)

USD 0.07B
DOCG:LSE L&G Healthcare Breakthrou.. 1.92 % 0.00 %

-12.75 (-2.35%)

USD 0.07B
HTEC Robo Global® Healthcare .. 1.89 % 0.00 %

-0.05 (-2.35%)

USD 0.06B
W311:XETRA HAN-GINS Indxx Healthcare.. 1.30 % 0.00 %

-0.05 (-2.35%)

USD 0.02B
W311:F HAN-GINS Indxx Healthcare.. 1.30 % 0.00 %

-0.01 (-2.35%)

USD 0.02B
WELL:PA HAN-GINS Indxx Healthcare.. 1.30 % 0.00 %

-0.01 (-2.35%)

N/A
ETHO Amplify ETF Trust 0.48 % 0.45 %

-0.04 (-2.35%)

USD 0.18B
ISMD Inspire Small/Mid Cap Imp.. 0.27 % 0.62 %

-0.02 (-2.35%)

USD 0.19B
WDNA 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 24.75% 80% B- 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.75% 80% B- 83% B
Trailing 12 Months  
Capital Gain 42.35% 84% B 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 42.35% 84% B 84% B
Trailing 5 Years  
Capital Gain 31.75% 72% C 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.75% 72% C 62% D
Average Annual (5 Year Horizon)  
Capital Gain 9.54% 64% D 66% D+
Dividend Return 9.54% 64% D 63% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 53.93% 54% F 34% F
Risk Adjusted Return 17.69% 74% C 53% F
Market Capitalization 0.21B 74% C 82% B

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 2.06 51% 46%
Price / Cash Flow Ratio 57.18 7% 5%
Price/Free Cash Flow Ratio -26.62 93% 94%
Management Effectiveness  
Return on Equity -4.88% 85% 54%
Return on Invested Capital -0.93% 83% 56%
Return on Assets 0.38% 83% 61%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector